Oncologists are starting to look at bureaucratic obstacles that contribute to the “devastatingly slow” pace of cancer clinical trials. Bureaucratic disqualifications and barriers contribute to low clinical trial participation; in Europe, regulation dramatically increases trial cost and time; and “misguided” use of IRBs contributes to study delays. Outsourcing to CROs reduces study startup times. Higher trial costs, in turn, contribute to higher drug costs. (Medscape)